SURPASS trial programme: difference between revisions
Diff·revision 6 → 7·19:05, 21 Sep 2024
Difference between revision 6 and revision 7 of SURPASS trial programme. 3 lines changed; the page grew by 330 bytes.
| Revision 6 — 00:53, 3 Sep 2024 CagriCass (talk) fix a dangling clause 2,281 bytes +288 | Revision 7 — 19:05, 21 Sep 2024 PioneerPerdita (talk) the trial was open-label; the article implied blinding 2,611 bytes +330 | ||
|---|---|---|---|
| 24 | SURPASS-CVOT is unusual among cardiovascular outcome trials in using an active comparator with an established benefit rather than placebo, which changes what a non-inferiority result means: non-inferiority to an agent that itself reduced events is a stronger statement than non-inferiority to placebo.{{r|frias2021}} | 24 | SURPASS-CVOT is unusual among cardiovascular outcome trials in using an active comparator with an established benefit rather than placebo, which changes what a non-inferiority result means: non-inferiority to an agent that itself reduced events is a stronger statement than non-inferiority to placebo.{{r|frias2021}} |
| 25 | 25 | ||
| + | 26 | Open-label design in SURPASS-2 is a limitation for subjective endpoints and adverse-event reporting, though less so for glycated haemoglobin, which is a laboratory measurement.{{r|ich_e9}} | |
| + | 27 | ||
| 26 | == References == | 28 | == References == |
| 27 | {{reflist}} | 29 | {{reflist}} |
| 28 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> | 30 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> |
| + | 31 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> | |
| 29 | 32 | ||
| 30 | {{DEFAULTSORT:SURPASS trial programme}} | 33 | {{DEFAULTSORT:SURPASS trial programme}} |